Drugs in R & D

, Volume 2, Issue 2, pp 116–117 | Cite as

PMS 812

S 21663
Section 1: Type 2 Diabete Mellitus Adis R&D Profile


Adis International Limited Piperazine Imidazoline MIN6 Cell Antidiabetic Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Wang X, Rondu F, Lamouri A, et al. Effect of S-21663 (PMS 812), an imidazoline derivative, on glucose tolerance and insulin secretion in a rat model of type II diabetes. J Pharmacol Exper Ther 1996 Jul; 278: 82–9Google Scholar
  2. 2.
    Rondu F, Le Bihan G, Wang X, et al. Structure-activity relationships in a series of substituted piperazines potentially active in non-insulin-dependent diabetes mellitus [abstract]. XIIIth International Symposium of Medicinal Chemistry. 1994 Sep 19–23; Paris, 263Google Scholar
  3. 3.
    Le Brigand L, Virsolvy A, Peyrollier K, et al. Stimulation of insulin release fromthe MIN6 cell line by a newimidazoline compound, S-21663: evidence for the existence of a novel imidazoline site in beta cells. Br J Pharmacol 1997 Oct; 122: 786–91PubMedCrossRefGoogle Scholar
  4. 4.
    Le Bihan G, Rondu F, Pelé-Tounian A, et al. Design and synthesis of imidazoline derivatives active on glucose homeostasis in a rat model of type II diabetes. 2. Syntheses and biological activities of 1,4-dialkyl-, 1,4-dibenzyl, and 1-benzyl- 4-alkyl-2-(4′,5′-dihydro-1′H-imidazol-2′-yl)piperazines and isosteric analogues of imidazoline. J Med Chem 1999 May 6; 42: 1587–603PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Personalised recommendations